← Back to Search

Monoclonal Antibodies

TL-925 Arm for Allergic Eye

Phase 2

Recruiting

Research Sponsored by Telios Pharma, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3, 5 and 7 minutes after cac

Awards & highlights

Study Summary

This trial will involve 70 participants who will be randomly assigned to receive either TL-925 eye drops or a placebo. The study will assess the effectiveness of TL-925 in treating allergic conjunctiv

Who is the study for?

This trial is for individuals with allergic eye conditions, specifically Allergic Conjunctivitis. Participants should have a confirmed diagnosis and be suitable for the conjunctival allergen challenge model used in this study.Check my eligibility

What is being tested?

The study tests TL-925 against a placebo to see if it's effective in treating Allergic Conjunctivitis. Subjects will receive either TL-925 or placebo as eye drops in both eyes, with outcomes compared to assess efficacy.See study design

What are the potential side effects?

Potential side effects of TL-925 are not detailed here but may include typical reactions associated with ophthalmic drugs such as irritation, redness, discomfort, or blurred vision.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3, 5 and 7 minutes after cac

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3, 5 and 7 minutes after cac

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 5 and 7 minutes after cac for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Conjunctival Redness

Ocular Itching

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: TL-925 ArmActive Control1 Intervention

Subjects will be dosed in clinic and at home.

Group II: Placebo ArmPlacebo Group1 Intervention

Subjects will be dosed in clinic and at home.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Telios Pharma, Inc.Lead Sponsor

9 Previous Clinical Trials

1,337 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being recruited for this ongoing medical study?

"According to clinicaltrials.gov, this research endeavor is presently not enrolling new participants. Originally announced on the 1st of March 2024, and most recently revised on the 27th of February 2024. Despite its current inactivity regarding recruitment, there exist sixteen additional clinical trials that are actively seeking eligible candidates for participation."

Answered by AI

Has the FDA given its approval for TL-925 Arm?

"Based on our evaluation at Power, the safety rating for TL-925 Arm is established at 2 due to being in a Phase 2 trial where some data affirms its safety but efficacy data is lacking."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study Of TL-925 For The Treatment of AC

2024. "A Study Of TL-925 For The Treatment of AC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06293820.

All > Paid Studies Boston